Glucagon-like peptide-1 receptor agonists emerge as a promising pharmacological intervention for weight reduction in end-stage kidney disease (ESKD) patients, potentially addressing the major barrier that obesity presents to kidney transplantation eligibility. The analysis highlights that patients requiring 20% or greater weight reduction benefit most from bariatric surgery, while traditional lifestyle interventions face significant limitations due to metabolic, physical, and psychosocial constraints unique to the ESKD population. This represents a critical advancement in transplant medicine, as kidney transplantation offers the best survival outcomes and quality of life for ESKD patients. The current obesity epidemic among dialysis patients creates a paradox where those who would benefit most from transplantation are systematically excluded. GLP-1 agonists like semaglutide have demonstrated remarkable efficacy in general populations, achieving 15-20% weight loss, but safety and efficacy data specifically in ESKD patients remains limited due to altered drug metabolism and clearance in kidney failure. The integration of these newer pharmacological tools with existing surgical options could dramatically expand the transplant candidate pool, though equitable access policies and insurance coverage remain significant hurdles that must be addressed to prevent further health disparities.